U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. John Gray’s Mars Venus LLC - 564498 - 02/05/2019
  1. Warning Letters

WARNING LETTER

John Gray’s Mars Venus LLC MARCS-CMS 564498 —

Product:
Dietary Supplements

Recipient:
Recipient Name
John Henderson Gray
John Gray’s Mars Venus LLC

20 Sunnyside Ave
Ste A130
Mill Valley, CA 94941
United States

Issuing Office:
Center for Food Safety and Applied Nutrition

5001 Campus Drive
College Park, MD 20740-3835
United States


WARNING LETTER

 

 

VIA OVERNIGHT DELIVERY

RETURN RECEIPT REQUESTED

 

February 5, 2018

 

John Gray’s Mars Venus LLC

John Henderson Gray

20 Sunnyside Ave

Ste A130

Mill Valley, CA 94941

 

13 Lyon Pl

Mill Valley CA 94941

 

RE: 564498

 

Dear Mr. Gray:           

This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.marsvenus.com in September 2018 and has determined that you take orders there for the products 2-AEP Membrane Complex, Ionic Silver Water, L-Glutathione, Liposomal DHA – Ultimate Omega-3 Brain Support, Liposomal Methyl B12/Folate, NAC N-Acetyl-L-Cysteine, and Vectomega.  FDA also reviewed your social media website at www.facebook.com/Mars.Venus.John.Gray, which provides a link to your website at www.marsvenus.com. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.  

Examples of some of the claims observed on your website that provide evidence your products are intended for use as drugs include the following:

On the page of your website titled “Glutathione Is The Master Antioxidant”:

  • “Glutathione … is the secret to preventing … heart disease, dementia and necessary to treat everything from ADHD, to autism to Alzheimer’s disease.”

On the page of your website titled “The Link Between Diabetes, Dementia and Alzheimer’s Disease”:

  • “These following steps are crucial to preventing Alzheimer’s disease and so effective, they could reverse the momentum of Alzheimer’s.

“7. Take folate, vitamin B-6 and vitamin B-12. These three nutrients can … reduce the risk of Alzheimer’s by half.

“8 . Take a daily Omega-3 supplement.

“12. Take N-acetyl-cysteine, or NAC…

“17. Take one capsule of 2-AEP Membrane Complex three times daily before each meal.”

On the page of your website titled “Cholesterol-lowering Drugs Have A Dark Side”:

  • “If you are taking a statin drug just because your cholesterol levels are high and you have no history of heart disease, reconsider taking it. There are much better ways to avoid a heart attack, including fish oil…”
  • Below this claim, there is a link that says, “CLICK HERE to learn more about the products discussed in this video.” This link goes to the website https://www.marsvenus.com/list/search/f%7E[high-cholesterol, which list several products, including Vectomega. The Vectomega product page states that “Vectomega contains up 50 times higher triglyceride fish oil than other omega oil supplements.”

On the product page, “Ionic Silver Water – Superior Mouthwash for Infections, Digestions & Candida Control”

  • “Ionic Silver Water helps you fight off a cold or flu…”
  • “Silver is the ultimate antidote to germs. Silver is often used in medicine to prevent infections, including with wound dressings, urinary catheters and breathing tubes.” 

On the product page, “NAC – Liver Health & Glutathione for Detoxification”

  • “‘Fights viral infections”
  • “NAC helps… protect the body from the damaging effects of chemotherapy, cigarette smoke…”

The claims quoted above are supplemented by the metatag keywords used to bring consumers to your website through Internet searches. The metatag keywords include:

  • For your 2-AEP Membrane Complex product: “asthma, migraine. . . . anxiety”
  • For your Ionic Silver Water: “silver antibiotics”
  • For your L-Glutathione : “heart disease, . . . necessary to treat everything from ADHD, to autism to Alzheimer’s disease. . . . cancer, alzheimers disease, autism, adhd, cancers, . . . mercury poisoning”
  • For your Liposomal DHA - Ultimate Omega-3 Brain Support: “parkinsons disease, alzheimers disease, alzheimers, . . . brain injury”
  • For your NAC N-Acetyl-L-Cysteine: “parkinsons disease, . . . alzheimers, cancer”

Furthermore, the following claims made on your Facebook page at https://www.facebook.com/Mars.Venus.John.Gray/, which provides a link to your website at www.marsvenus.com, provide additional evidence that your products are intended for use as drugs: 

  • On May 28, 2018, and January 8, 2018, you posted the following: “Omega-3s can help … lift you out of depression.” This post links to a webpage on your website titled “Liposomal DHA, Omega-3 for … Dementia, Alzheimers.”

Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.

A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.

Your products 2-AEP Membrane Complex, Glutathione, Liposomal DHA – Ultimate Omega-3 Brain Support, Liposomal Methyl B12/Folate, NAC N-Acetyl-L-Cysteine, and Vectomega are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, 2-AEP Membrane Complex, Black Seed, Glutathione, Liposomal DHA – Ultimate Omega-3 Brain Support, Liposomal Methyl B12/Folate, NAC N-Acetyl-L-Cysteine, and Vectomega fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].

The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. 

You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.

Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

Your written reply should be directed to Shawn Goldman, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, please contact Mr. Goldman at Shawn.Goldman@fda.hhs.gov.

 

Sincerely,

/S/

William A. Correll, Jr.
Director
Office of Compliance
Center for Food Safety and Applied Nutrition

 

cc:
John Gray's Mars Venus LLC John Henderson Gray
13 Lyon Pl